We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more
Ask ADVFN Intelligence (AI)
SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional...
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.28 | 1.41987829615 | 19.72 | 20.4 | 18.745 | 599095 | 19.41860216 | CS |
| 4 | 0.34 | 1.72939979654 | 19.66 | 20.5 | 17.5 | 704241 | 19.16227497 | CS |
| 12 | -4.45 | -18.200408998 | 24.45 | 29.56 | 17.5 | 924079 | 22.07380684 | CS |
| 26 | -2.37 | -10.5945462673 | 22.37 | 29.56 | 17.5 | 783217 | 22.70030889 | CS |
| 52 | 11.81 | 144.2002442 | 8.19 | 29.56 | 7.65 | 890088 | 18.6059123 | CS |
| 156 | 1.07 | 5.65240359218 | 18.93 | 29.56 | 4.22 | 599818 | 14.73376894 | CS |
| 260 | -0.25 | -1.23456790123 | 20.25 | 52.38 | 4.22 | 513020 | 18.47740621 | CS |
Monksdream
3 months ago
Monksdream
4 months ago
Monksdream
4 months ago
Monksdream
7 months ago
Monksdream
7 months ago
Monksdream
8 months ago
Monksdream
10 months ago
Monksdream
10 months ago
Monksdream
11 months ago
TheFinalCD
2 years ago
infamous
4 years ago
Phosphene
4 years ago
Phosphene
4 years ago
Phosphene
4 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
